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A b s t r A c t
Transvenous temporary cardiac pacing is a rather old but still contemporary life-sav-
ing technique, with a unique value in the treatment of critically ill patients suffering 
from rhythm disturbances and associated hemodynamic compromise. Physicians in-
volved in the management of such patients should always keep in mind the indications 
and contraindications of transvenous temporary cardiac pacing, and should be at least 
familiar with the insertion technique and the post-insertion care.
I n t r o d u c t I o n
Temporary cardiac pacing is a life-saving procedure used as a means of electrical 
stimulation of the heart through the use of pacing leads, in order to treat dysrhythmias, 
until they are resolved or until a long-term therapy is adopted.1-5 Temporary pacing is 
effected via transvenous, transcutaneous, or epicardial approaches. Transcutaneous 
pacing is delivered via cutaneous adhesive pads placed in an anteroposterior position, 
has the advantage of being immediately available for emergency cases of asystole but 
it requires high energy to capture the heart, causing significant discomfort to the wake 
patient, and is reserved for those who are comatose or as a bridge until transvenous 
endocardial pacing is rendered feasible.1,5,6 Epicardial wires are routinely placed during 
cardiac surgery to provide backup pacing in the event of perioperative bradyarrhyth-
mias, but also to diagnose and overdrive certain tachyarrhythmias (e.g. atrial flutter).7 
However, the most common and reliable approach to temporary pacing is provided 
with transvenous insertion of temporary pacing wire.1-5 
Transvenous temporary cardiac pacing (TCP) was first described by Furman et al 
in 1958 in dogs and in 1959 in human beings,8,9 initially for the correction of complete 
heart block, but the indications have subsequently expanded to comprise a variety 
of bradyarrhythmias but also a list of tachyarrhythmias, including the diagnosis and 
overdrive suppression of supraventricular and ventricular tachycardias.1,3,4 In its most 
common use of supporting the patient with bradycardia, temporary pacing typically 
serves as a bridge to a more definitive solution to a low heart rate, such as permanent 
pacemaker implantation, or resolution of a transient or reversible cause, e.g. brady-
cardic effect of drugs, electrolyte disturbance, inferior-wall myocardial infarction, etc. 
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List of AbbreviAtions
AMI = acute myocardial infarction
AV = atrio-ventricular
BBB = bundle branch block
CHB = complete heart block
ECG = electrocardiogram
LAFB = left anterior fascicular block
LBBB = left bundle branch block
LPFB = left posterior fascicular block
RA = right atrium
RBBB = right bundle branch block
RV = right ventricle
SVT = supraventricular tachycardia
SuVT = sustained ventricular tachycardia
TCP = temporary cardiac pacing
TdP = torsade de pointes
* Reproduced with permission from Poulidakis E & Manolis AS. Transvenous Temporary Cardiac Pacing. Rhythmos 2014;9(2); 20-27.
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I n d I c A t I o n s
Transvenous temporary cardiac pacing is most com-
monly used to treat symptomatic bradycardia due to sinus 
node dysfunction or atrioventricular (AV) block. In general, 
indications could be divided into those associated with acute 
myocardial infarction (AMI), and those not linked to AMI.1,10 
The former are clearly outlined in the American Heart As-
sociation guidelines for AMI management,11 and presented in 
Table 1. It should be noted, that in a patient with AMI, a more 
aggressive management of bradycardia is warranted in order 
to maintain an adequate coronary blood flow in the infarcted 
myocardium. However, special precautions should be taken 
in a patient who has undergone thrombolysis, such as using 
different access site or using transcutaneous pacing. Also, in 
the more recent AHA 2010 Guidelines,12 for the management 
of cardiac arrest, the routine use of pacing in asystole is listed 
as a grade III recommendation. 
In the setting of an AMI, the benefits of transvenous TCP 
should be weighed and balanced against the higher risk for 
bleeding if the patient has recently received thrombolysis or 
is on heparin and/or other antithrombotics during the process 
of primary percutaneous coronary intervention (PCI). If the 
patient remains hemodynamically stable, transcutaneous 
pads could be used as backup instead. In general, due to the 
adoption of rapid reperfusion therapies over the recent years 
(e.g. primary PCI),11 and also due to observed higher risk of 
complications of TCP in the setting of AMI (e.g. ventricular 
tachyarrhythmias),13 and with the availability of transcutane-
ous pacing, transvenous TCP use has significantly declined 
to <1%.14
Beyond the use of pacing in the setting of AMI, the indica-
tions of transvenous TCP are similar to those of permanent 
pacing,15 especially when the latter is not immediately available 
or finally not indicated, such as in bradycardia due to reversible 
causes (Table 2). Nevertheless, in such cases transvenous TCP 
should be reserved for patients with hemodynamic compro-
mise, episodes of asystole or tachyarrhythmias in response to 
bradycardia, such as polymorphic ventricular tachycardia in 
the form of torsarde de pointes (TdP) in the setting of long QT 
interval. The application of TCP in asymptomatic and hemo-
dynamically stable patients with good escape rhythms may 
render these individuals pacemaker dependent, and in case 
pacing fails, asystole could occur. In addition, there is the risk 
of infection in the access site, that could possibly be used later 
for permanent pacing.1,3 A special cautionary note concerns 
tAblE 1. Recommendations for Temporary Transvenous 
Pacing in the Course of AMI11
class I
1. Asystole 
2. Symptomatic bradycardia (includes sinus bradycardia with hy-
potension & type I 2o AV block with hypotension not respon-
sive to atropine)
3. Bilateral BBB (alternating BBB or RBBB with alternating 
LAFB/LPFB) (any age)
4. New or indeterminate age bifascicular block (RBBB with 
LAFB or LPFB, or LBBB) with 1o AV block
5. Mobitz type II 2o AV block
class lla 
1. RBBB and LAFB or LPFB (new or indeterminate)
2. RBBB with 1o AV block
3. LBBB, new or indeterminate
4. Incessant VT, for atrial or ventricular overdrive pacing
5. Recurrent sinus pauses (>3 s) not responsive to atropine
class IIb
1. Bifascicular block of indeterminate age
2. New or age-indeterminate isolated RBBB
class III
1. 1o heart block
2. Type I 2o AV block with normal hemodynamics
3. Accelerated idioventricular rhythm
4.	BBB	or	fascicular	block	known	to	exist	before	ΑMI
AMI = acute myocardial infarction; AV = atrio-ventricular; BBB = 
bundle branch block; LAFB = left anterior fascicular block; LBBB = 
left bundle branch block; LPFB = left posterior fascicular block; RBBB 
= right bundle branch block; VT = ventricular tachycardia.
tAblE 2. Indications for Temporary Cardiac Pacing
Acute MI bradyarrhythmias tachyarrhythmias
Asystole Asystole / CHB Torsades de pointes
CHB Symptomatic sinus 
bradycardia  
(<40 bpm)
SVT
Mobitz II  
AV block
Prolonged sinus  
pauses (>3-4 s)
SuVT
(see Table 1) PPM failure/ 
replacement
(see Table 3)
AV = atrioventricular; CHB = complete heart block; MI = myocardial 
infarction; PPM = permanent pacemaker; SuVT = sustained ventricu-
lar tachycardia; SVT = supraventricular tachycardia.
192
HOSPITAL CHRONICLES 9(3), 2014
patients, more commonly women, presenting with complete 
heart block, who have increased propensity to develop TdP 
unassociated with QT prolonging drugs.16 Thus, in patients 
presenting with acquired complete heart block and low heart 
rate, even when hemodynamically stable or oligosymptomatic, 
it may be prudent to use prophylactic transvenous TCP in all of 
them, while waiting for a permanent pacemaker, to avoid this 
worrisome scenario of bradycardia-induced long QT and TdP. 
Reversible causes of bradycardia, where transvenous TCP 
should be considered, are listed in Table 3.3,4,15
Transvenous TCP might be necessary in patients fitted 
with a permanent pacemaker if permanent pacing fails, or 
when pacemaker-dependent patients undergo pulse gen-
erator replacement.1 Moreover, TCP might be considered 
in ambiguous cases to verify the potential benefit of possible 
permanent pacing. In rare cases dual-chamber DDD TCP 
with use of an additional atrial lead with a preformed j-curve 
positioned in the right atrial appendage under fluoroscopy 
guidance has been employed to improve cardiac output in 
patients who have lost AV synchrony;1,3,4 alternatively, VDD 
pacing via a single atrial-sensing ventricular-pacing lead has 
been proposed for use in patients with acute sepsis and heart 
failure;18 at the same time there are scarce reports about the 
use of temporary biventricular pacing in cases of refractory 
cardiogenic shock.19 Elective use of transvenous TCP has been 
reported in patients with underlying conduction abnormal-
ity (such as “trifascicular” block), who undergo non-cardiac 
surgery or high risk angioplasty in the right coronary artery.1 
When TCP is unexpectedly needed during the performance 
of a PCI procedure, pacing can be accomplished faster using 
the coronary artery guidewire, as an alternative to insertion of 
a transvenous temporary pacemaker.20 Finally, during newer 
types of percutaneous procedures, such as transcatheter aortic 
valve implantation (TAVI), transvenous TCP is employed for 
both prophylaxis for the occurrence of heart block (standby 
tAblE 3. Temporary Pacing for Reversible Causes of 
Bradycardia
1. Metabolic or electrolytes abnormalities (hypothyroidism, hypo-
thermia, hyperkalemia) 
2. Drug induced bradycardia (beta blockers, calcium channel 
blockers, digitalis, amiodarone)
3. Injury to the sino-atrial node or to other parts of the conduction 
system, after cardiac surgery, heart transplantation, radiofre-
quency ablation of arrhythmias or cardiac trauma during motor 
vehicle accident; ischemia (inferior-wall AMI)
4. Other diseases associated with temporal injury to the conduc-
tion system, such as Lyme’s disease, or endocarditis with an aor-
tic valve abscess (early ECG sign: 1o AV block).
pacing) and for facilitation of balloon valvuloplasty and/or 
balloon-expansion of the artificial valve (rapid pacing).21,22
An important, albeit less known or less frequently em-
ployed, use of transvenous TCP relates to the management 
of tachyarrhythmias. In the setting of sick sinus syndrome 
or prolonged QT interval, rapid pacing (90-110 bpm) could 
minimize the incidence of atrial fibrillation, and polymorphic 
ventricular tachycardia (TdP), respectively. In addition, sev-
eral tachyarrhythmias, such as supraventricular tachycardia, 
atrial flutter or monomorphic ventricular tachycardia could 
be terminated with overdrive pacing, which involves pacing 
at slightly faster rates than the tachycardia rate.1,2,23 Overdrive 
pacing requires expertise, as inadvertent implementation could 
lead to acceleration of the tachycardia.1,2 
c o n t r A I n d I c A t I o n s
Transvenous TCP should be avoided when the possible 
risks outweigh the potential benefits, such as in asymptomatic 
stable patients or in those which excessive bleeding risk, es-
pecially after thrombolysis administration. The presence of a 
prosthetic tricuspid valve is an absolute contraindication, while 
infarction of the right ventricle could minimize the possibility 
of successful pacing capture.1
I n s E r t I o n  t E c H n I Q u E
The physicians who are credentialed to place a temporary 
pacemaker should be familiar with the insertion equipment 
(puncture needle and sheath), electrode-catheters and con-
nectors, and the external pulse generator available in their 
own hospital settings. Apart from understanding the indica-
tions of temporary cardiac pacing (Tables 1-3) and acquiring 
the technical skill of safe vessel puncture and lead insertion, 
another very important aspect is how capable and knowledge-
able the physician is in order to recognize the morphology of 
the endocardial electrograms of the superior vena cava, right 
atrium, and right ventricle and use this electrocardiographic 
(ECG) monitoring to guide proper pacing lead positioning.2, 24 
t r A n s v E n o u s  A c c E s s
Access sites for transvenous pacing include the internal 
jugular, subclavian, femoral and even the antecubital or bra-
chial veins. The internal jugular vein is favored by some as it 
may be associated with fewer complications and spares sub-
clavian access for future permanent pacemaker placement.1,25 
However, patient convenience and maintenance of site sterility 
may be less than desirable. The subclavian route appears to be 
a more stable position and provides a more convenient site for 
patient mobility.26 The femoral vein is generally undesirable 
due to increased incidence of deep vein thrombosis and infec-
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tion. However, during cardiac procedures performed in the 
catheterization or the electrophysiology laboratory, this site is 
a readily accessible site, albeit for cases requiring pacing cover-
age for a very short duration. If the need for temporary pacing 
coverage is expected to be of longer duration, then the tempo-
rary pacing lead initially inserted via the femoral access should 
be exchanged with a more stable position, e.g. the subclavian 
route, at the end of the main procedure. Finally, the external 
jugular, brachial or antecubital and femoral veins may be used 
in special circumstances, mostly after thrombolysis.1 With the 
availability of 4 o 5Fr balloon-tipped electrode catheters, the 
use of the antecubital (median basilic) vein may be a safer and 
more convenient approach, through which a transvenous TCP 
lead can be inserted and placed endocardially with relative ease 
when guided by ECG monitoring (see below) conferring fewer 
complications, especially in patients at risk for hemorrhage or 
when a less well trained physician is involved. 
G u I d A n c E
After obtaining transvenous access, a single balloon-tipped 
bipolar electrode-catheter (4-5Fr) may be used.2,27 This tem-
porary pacing lead can be introduced transvenously without 
fluoroscopy in a bedside procedure, similar to a Swan-Ganz 
catheter insertion aided by blood flow directing placement of 
the balloon-tipped catheter or via electrocardiographic moni-
toring. Of course, placement of a temporary pacing wire with 
use of fluoroscopy is easier and safer due to direct visualization 
of the lead, and it would be preferable if a procedure room is 
readily available next to the cardiac care unit or in the vicinity 
of the patient’s whereabouts. Use of fluoroscopy may become 
necessary when the other approaches fail and the patient is 
then transferred to the catheterization or electrophysiology 
laboratory to perform the procedure. In this case a hard-tipped 
bipolar electrode catheter can be used and maneuvered under 
visualization into the right ventricular apex. 
Without fluoroscopic imaging, a balloon-tipped pacing lead 
is employed and advanced “blindly” with the external pulse 
generator switched on, guided by the length of the catheter 
insertion and/or observing after each pacing spike for the 
appearance of ventricular capture with a left bundle branch 
morphology on 12-lead ECG confirming the correct placement 
of the lead within the right ventricle. While any site within the 
right ventricle, except for the high right ventricular outflow 
tract sites, will provide adequate pacing threshold and safe 
temporary pacing, placement of the pacing wire at the right 
ventricular apex will afford the greatest lead stability.
Newer active fixation temporary pacing wires have been 
advocated for better lead stabilization, but require more op-
erator expertise and their safety has not been corroborated. 
Others have proposed the use of a permanent pacing lead 
inserted with use of a stylet similar to the procedure of a 
permanent pacing lead insertion and connected to a used or 
old permanent pacemaker pulse generator adhered exter-
nally to the chest. This approach may be particularly useful 
for pacemaker-dependent patients undergoing pacing lead 
extraction and pacemaker removal due to infection and thus 
bridged until a new permanent pacemaker is implanted on the 
contralateral side.28-31
E l E c t r o c A r d I o G r A p H I c  M o n I t o r I n G
A more effective and safe, albeit a bit more time consum-
ing, approach utilizes the pacing bipolar electrode catheter as 
an ECG lead to monitor the advancement and correct endo-
cardial placement of the pacing lead by observing the changes 
in the endocardial electrogram pattern during passage of the 
catheter through the right heart chambers.2,24 This can be easily 
accomplished by connecting the distal (negative) pole of the 
lead with one of the precordial leads (e.g. V1 or V2) of the 
ECG with use of alligator connectors (crocodile clips) to record 
a unipolar ECG lead; alternatively, the distal electrode can be 
connected to the right arm lead and the proximal electrode to 
the left arm lead to record a bipolar lead I electrocardiogram. 
Recording of a QS pattern indicates traversing the tricuspid 
valve, at which point the balloon is deflated and the lead is ad-
vanced with a clock-wise rotation to direct it towards the apex 
and make contact with the endocardium, which is confirmed 
by the appearance of ST elevation (current of injury pattern) 
on the endocardial electrogram (Fig. 1). If the balloon is not 
deflated in time, the lead will further advance to the outflow 
tract and the pulmonary artery; a position in the outflow tract 
is prone to dislodgement and less reliable pacing. Upon re-
cording of a QS/ST elevation type of intracardiac electrogram, 
connection of the lead is switched to the external pacemaker 
device and pacing threshold testing is performed. A pacing 
threshold <1 mA attests to excellent endocardial contact of 
the pacing lead. 
This ECG-guided approach can only be applied in patients 
who have an underlying native (escape or other) rhythm and, 
of course, not in patients with ventricular asystole. During the 
insertion process, a loop in the right atrium may be formed 
and pose difficulty in further advancing the lead; this is best 
avoided by paying attention to the length of the lead being 
advanced (>30-40 cm), in which case the lead is withdrawn 
(with the balloon deflated) and the process repeated. During 
monitoring of the endocardial ECG, the appearance of an R 
wave should raise the suspicion of possible perforation, when 
the lead is immediately withdrawn and the patient monitored 
for possible hemopericardium or tamponade; in the majority 
of cases this remains uneventful. After final lead placement, 
some have suggested partial inflation of the balloon that could 
reduce the risk of perforation. At this point obtaining a 12-lead 
ECG can further confirm correct lead placement close to the 
right ventricular apex, by recording a pacing rhythm with LBBB 
pattern with superior (left) axis; recording a RBBB pattern 
indicates epicardial pacing either via a perforating lead or a 
lead inserted inadvertently into the middle cardiac or other 
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coronary vein (Fig. 2). Note also that echocardiography may 
be another, less often used option, for lead guidance.4
When the lead is in place, the external generator is securely 
connected to it, and the appropriate pacing mode is selected 
(usually VVI). The capture and sensing thresholds are be-
ing tested as described above. In an emergency, the highest 
output should be tried first (e.g. 15-20 mA); it should then 
be gradually reduced until capture is lost. If the situation is 
not an emergency, the rate is set 10-20 beats/min above the 
intrinsic heart rate, and the output is initially set very low and 
then gradually increased until capture occurs or set high and 
gradually decreased until capture is lost. The output should 
be set to a value at least 2-5 times higher than the threshold 
to ensure a safe margin for any change that occurs in the 
capture threshold, which is usually less than 1 mA. A position 
with low pacing threshold (≤1 mA) should be sought; a high 
pacing threshold >5 mA in the right ventricular lead indicates 
a need for repositioning. A slightly higher capture threshold 
is acceptable for atrial leads because they are less stable than 
ventricular leads. 
To check the sensing threshold (if it is needed in the de-
mand pacing mode), the pacing rate should be set lower than 
the intrinsic heart rate. The value of the sensitivity setting 
should then be gradually increased until the pacemaker fails to 
sense the intrinsic activity and consequently begins firing. The 
sensing threshold is usually more than 5 mV in the ventricle 
and is much lower in the atrium. The final sensitivity should 
then be set at a low value (high sensitivity) to effect adequate 
sensing of native electrical activity including extrasystoles and 
thus avoid inappropriate pacing and arrhythmia triggering. On 
the other hand, the sensitivity setting should not be too low 
(indicating high sensitivity) as the external pacemaker devices 
are more prone to electromagnetic interference from various 
external sources and equipment in the intensive care unit (e.g. 
respirators, monitors, even mobile or wireless phones, etc.) 
and thus risk pacemaker inhibition. In case of pacemaker 
dysfunction in the form of absent pacing, one should discern 
between visible pacemaker spikes that do not capture, which 
points to increased threshold or lead dislodgment, and absent 
pacing spikes which indicates disconnected leads or pacemaker 
inhibition due to oversensing; when proper connections are 
confirmed, increasing the sensitivity setting or selecting a VOO 
FIGurE 1. Lead V2 displays the endocardial electrogram (EGM) during passage of the pacing lead from the right atrium (left panel) 
to the right ventricle (right panel); transition is indicated by the QS pattern of the EGM and the ST elevation (arrow).
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FIGurE 2. When the pacing lead lies within the right ventricle, pacing produces a LBBB-like QRS morphology (left panel); when it 
has inadvertently entered the left ventricle or an epicardial coronary vein (e.g. the middle cardiac vein), pacing produces a RBBB-like 
QRS morphology (right panel). LBBB = left bundle branch block; RBBB = right bundle branch block.
stable, except for their need for temporary pacing, an entirely 
different strategy is proposed, as described above, rendering 
them capable for early ambulation. 
c o M p l I c A t I o n s
Although the complication rate of temporary cardiac pac-
ing has been reported to be as high as 32-35% in British and 
Danish studies,32,33 especially for less experienced operators, 
more commonly this rate is limited to 2%-10%. Complica-
tions may comprise local access bleeding, air embolism, nerve 
damage, pneumothorax or hemothorax during the subclavian 
puncture, hemopericardium and pericardial tamponade, atrial 
and ventricular arrhythmias during catheter insertion, includ-
ing atrial fibrillation and occasionally ventricular tachycardia 
and ventricular fibrillation; this is why an external defibrillator 
should always be present during TCP.1,3,4 A more common 
complication relates to post-procedural lead displacement 
resulting in loss of pacing capture and need for re-intervention. 
An important and avoidable, albeit risky, complication relates 
to infection leading to bacteremia and endocarditis. Thus, an 
aseptic technique and antiseptic measures during the proce-
dure, avoidance of the femoral route and diligent local care 
and vigilance post-procedurally are of utmost importance to 
avoid this potentially dangerous complication. Emergence 
of pericardial pain and an audible pericardial rub dictates a 
need for repositioning; fortunately, rarely does this condition 
lead to tamponade. 
mode might correct the oversensing problem. Finally, the AV 
interval in AV sequential pacing is usually set between 100 and 
200 ms, which is comparable to a normal PR interval.4
E n t r y  s I t E  /  p E r I - p r o c E d u r A l  c A r E
At the end of the procedure, the introducing sheath should 
be carefully removed from the vein and moved all the way back 
to the proximal end of the pacing lead, since leaving the intro-
ducer in place may be an important gate of bacteria entry and 
infection. A first suture is placed at the entry site to secure the 
lead in place, but also a second suture is even more important 
to be placed at a small wire loop created just a bit more proxi-
mally (to prevent lead dislodgment from accidental pulling), 
all contained within the sterile field which should subsequently 
be covered with a sterile dressing. The remaining length of the 
pacing wire can be looped and secured in the ipsilateral arm 
of the patient together with the connectors and the external 
pacing device, so that the patient could ambulate early, if 
clinically deemed appropriate, rather than sentenced to being 
bed ridden. Leaving the sheath in place and using long sleeves 
over the pacing wire has been suggested by some as convenient 
for repositioning the pacing wire in case of displacement, in 
analogy to the sleeve used for the Swan-Ganz catheter. This 
strategy should though be limited to those patients who are 
bed ridden, hemodynamically unstable, perhaps on respiratory 
support in the intensive care unit, but this approach may confer 
an increased risk of infection. For patients who are otherwise 
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p o s t- p r o c E d u r A l  pA t I E n t  c A r E 
Most studies have shown a relatively low rate of infection 
during the first week of transvenous temporary pacing. Howev-
er, when there is need for longer duration of temporary pacing, 
the complication rate may increase. Infection can be reduced 
by avoiding femoral access and maintaining high standards of 
local access care. There has accumulated significant experi-
ence from the time when electropharmacological tesing was 
routinely performed in patients with ventricular tachyarrhyth-
mias to test the efficacy of anti-arrhythmic drugs, before the 
implantable defibrillator became more widely available. At 
that time, after the first (primary) electrophysiology study, a 
small (4 or 5F) bipolar temporary wire was routinely inserted 
via the subclavian vein and placed at the right ventricular apex, 
which stayed in place for the duration of the period of drug 
testing via repeat sessions of programmed stimulation, which 
occasionally could last 3-4 weeks. Carefully sterile initial pro-
cedure and meticulous local care of the access site (cleaning 
and dressing change), together with daily cardiac auscultation 
for the appearance of pericardial rub and periodic threshold 
testing of the pacing wire and/or recording of the endocardial 
electrogram when needed, resulted in only rare occurrence of 
infections or other complications, or at least these measures 
permitted early recognition of such complications. Finally, 
recording the time of replacement of batteries of the external 
pacemaker device by placing a label on the device and watch-
ing for battery depletion, as well as securing and conducting 
surveillance of the lead connections to the pacemaker device 
are also other important measures to both prevent and detect 
further problems. 
The connections of the lead with the pulse generator should 
be securely attached and the generator should be secured in 
place to prevent an unexpected drop in the ground. Attaching it 
to the patient’s arm would be ideal, in an ambulatory patient.4,34 
Thorough care should be implemented to prevent infection. 
Use of antiseptic and a sterile, preferably transparent, dressing 
at the access site is of utmost importance; the entry site should 
be cleaned and the dressing changed daily.34 Routine use of 
prophylactic antibiotics is not necessary unless there is a sign 
of infection, pacing is prolonged (>7 days) or femoral access is 
used. Twelve-lead-ECG, pacing and sensing thresholds should 
be assessed daily, as they fluctuate over time. Threshold testing 
in pacemaker dependent patients (with >90% pacing) should 
be performed with caution. Whenever there is a suspicion of 
lead dislodgement a new chest x-ray should be ordered.1,4,34 
Indeed, transvenous TCP, using standard temporary wires, 
has been plagued with loss of capture more frequently com-
pared to the very low risk with permanent pacemakers. The 
patient should be maintained on telemetry for the duration of 
temporary pacing. This caveat together with the declining skill 
and capability of operators, mainly due to lack of training,35, 
36 all culminating into an inordinate rate of complications of 
transvenous TCP in some, mostly European, countries, is the 
main reason why some clinicians have declared this life-saving 
procedure as an “orphan” and advocated a 24-hour permanent 
pacemaker implantation service.36,37 However, this strategy may 
lead to a hastened decision regarding the need for permanent 
pacemaker, poses the risk of missing indolent infection with 
subsequent severe consequences of device infection, and also 
missing other serious underlying disorders which may come up 
when the routine pre-procedural test results become available 
at a later time. Since, there is definitely a way to make TCP a 
safe procedure and durable process, educational bodies and 
societies should aim at restructuring the training guidelines 
for TCP, rather than compromising patient safety with hasty 
and frivolous approaches. 
p H y s I c I A n  t r A I n I n G
Currently, there are limited guidelines on training require-
ments to achieve competency on temporary cardiac pacing. 
The Accreditation Council for Graduate Medical Education 
(ACGME) guidelines recommend that residents perform 
6 cardiac pacing attempts during residency training, either 
in patients or simulators, but make no distinction between 
transcutaneous or transvenous pacing.38 According with the 
joint statement released in 1994 by the American College 
of Physicians, American College of Cardiology (ACC), and 
American Heart Association (AHA) regarding clinical com-
petence in insertion of a transvenous TCP, a minimum of 10 
TCP procedures are required of the trainee.39 Over the recent 
years, it has become apparent that simulation techniques are 
adequate and effective in measuring procedural competency 
and may thus constitute a substitute of “hands on” patient 
practice and experience as a training tool for physicians in 
various procedures, including training on transvenous TCP.38 
In the US, medical and surgical residents usually receive train-
ing right from the start in their first year of residency how to 
place a transvenous TCP lead, and thus there is usually no 
need to call upon a cardiology fellow or attending physician 
to perform the procedure except for difficult cases. However, 
in Europe and other parts of the world, this task is relayed 
to a cardiologist rather than a physician of other specialties. 
In either case, adequate training is the key to successful and 
safe performance of this life-saving procedure.40 In addition 
to cardiologists, other specialists with an aptitude for this 
procedure may be emergency medicine physicians, intensivists, 
and anesthesiologists. 
c o n c l u s I o n
Transvenous temporary cardiac pacing is an indispensa-
ble treatment modality for the acute treatment of a variety 
of dysrhythmias, mostly bradyarrhythmias, and therefore it 
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is considered a critically important skill for the clinician. Its 
implementation, however, requires both competent inter-
ventional skills and experience in cardiac pacing, as well as 
continuous care after the successful insertion, in order to 
maximize the potential benefit for the patient and to mitigate 
the risk of complications. 
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